SERP
Comments:
FGFR4-IN-8B is a covalent inhibitor of FGFR4 kinase with minimal activity over FGFR1-3 isoforms that lack the reactive cysteine that the compound targets. Based on two separate kinome-screening methods, FGFR4-IN-8B has very good kinase selectivity. A FGFR NanoBRET assay indicated high isoform selectivity in mammalian cells and potent antiproliferative activity in Hep3B cells further suggest robust target engagement. Liver microsome assays indicate that the compound is metabolically relatively stable, but in vivo activity is not tested. In conclusion, FGFR4-IN-8B is a highly isoform-selective covalent FGFR4 inhibitor suitable for cellular experiments. A nonreactive control compound, cpd14A, is reported with minimal activity against FGFR4.
(last updated:
8 Jul 2024 )